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Abstract
Background: There is significant morbidity and mortality caused by the complications of osteoporosis, for which ageing is
the greatest epidemiological risk factor. Preventive medications to delay osteoporosis are available, but little is known about
motivators to adhere to these in the context of a symptomless condition with evidence based on screening results.
Aim: To describe key perceptions that influence older women’s adherence and persistence with prescribed medication
when identified to be at a higher than average risk of fracture.
Design of Study: A longitudinal qualitative study embedded within a multi-centre trial exploring the effectiveness of
screening for prevention of fractures.
Setting: Primary care, Norfolk. United Kingdom
Methods: Thirty older women aged 70–85 years of age who were offered preventive medication for osteoporosis and
agreed to undertake two interviews at 6 and 24 months post-first prescription.
Results: There were no overall predictors of adherence which varied markedly over time. Participants’ perceptions and
motivations to persist with medication were influenced by six core themes: understanding adherence and non-adherence,
motivations and self-care, appraising and prioritising risk, anticipating and managing side effects, problems of
understanding, and decision making around medication. Those engaged with supportive professionals could better
tolerate and overcome barriers such as side-effects.
Conclusions: Many issues are raised following screening in a cohort of women who have not previously sought advice
about their bone health. Adherence to preventive medication for osteoporosis is complex and multifaceted. Individual
participant understanding, choice, risk and perceived need all interact to produce unpredictable patterns of usage and
acceptability. There are clear implications for practice and health professionals should not assume adherence in any older
women prescribed medication for the prevention of osteoporosis. The beliefs and motivations of participants and their
healthcare providers regarding the need to establish acceptable medication regimes is key to promoting and sustaining
adherence.
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Introduction
There is significant morbidity and mortality caused by the
complications of osteoporosis, for which ageing is the greatest
epidemiological risk factor. While other risks such as immobility,
persistent low body weight, early menopause and corticosteroid
use may lead to early onset of osteoporosis, around 40% of women
aged 70 will have osteoporosis, and as many as 90% will have a
significantly increased risk of fracturing a bone in a fall or accident
[1], [2]. This has led to a major research focus on the prevention
of osteoporosis which has established that osteoporotic fractures
can be significantly reduced by a combination of pharmacological
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(bisphosphonates with calcium and vitamin D supplements) and
behavioural interventions (dietary intake, smoking cessation, and
weight bearing exercise).
More recent initiatives include the development of treatment
algorithms and encouragement for primary care practitioners to
identify patients who may be at ‘risk’ of fracturing and may benefit
from preventive options [3],[4]. However, as the National Institute
for Clinical Excellence (NICE) acknowledge, ‘‘identifying who will
benefit from preventative treatment is imprecise’’ [5]. No population
screening programme currently exists for osteoporosis risk, and
individuals are identified clinically on a case by case basis.
Predictive risk of fracture compared to the norm for age and sex
can now be calculated using clinical risk factors in conjunction
with bone mineral density (BMD) measurements using Dual
energy X-ray Absorbtiometry (DXA) scans [6], [7], creating new
opportunities to identify individuals yet to sustain a fracture.
For screening to be effective, participants identified as high risk
must be receptive to the intervention. Achieving long-term
adherence to prescribed medications is more complex than just
providing sufficient information or an acceptable medication
regimen. The literature suggests adherence is highly variable in
osteoporosis prevention with age and co-morbidity explaining
relatively little of the variability [8], [9]. Attempts to reduce
complexity in dosing regimens do not necessarily improve
adherence [10], [11]. Patients are recommended to take their
bisphosphonates first thing in the morning before eating or
drinking and with a glass of water. There is a requirement for
them to remain upright for 30 minutes to avoid irritation to the
oesophagus. Calcium supplements are frequently provided in the
form of chewy tablets. Patients may understand the potential for
osteoporosis to have a negative effect on their lives, and express
strong motivation to protect their health, but this does not always
align with taking medications [12], [13]. This therefore makes the
motivations and decision making of older women around uptake
of preventive medication of primary importance to the public
health impact of any potential screening programme as well as to
the individual patient.
It is also known that patterns of adherence to osteoporosis
medications vary over time [14], [15]. However, a survey of
patients and physicians showed that poor adherence reflected
patient scepticism about the risks and values of treatment, rather
than a lack of factual knowledge. A qualitative synthesis of studies
on lay experience of medicine taking found widespread caution
about taking medication with many participants ‘testing’ pre-
scribed medicines for efficacy and adverse side effects [14]. Our
pilot study found as many as 50% of women at ‘high risk’ of
fracture in the 70–85 age group were not receiving treatment four
months later [16]. We therefore undertook this study to explore
the factors that influence older women’s adherence to prescribed
prophylactic medication when assessed to have higher than
average risk of fracture following screening. This paper describes
the perceptions and motivations to which participants attributed
their willingness and ability to adhere to osteoporosis prevention
regimes, and considers implications for practice.
Methods
Participants and procedure
The Adherence To Osteoporosis Medication (ATOM Study)
was established as a longitudinal qualitative study embedded
within the Medical Research Council funded UK multi-centre
randomised control trial on Screening for Osteoporosis in Older
Women for the Prevention of Fractures (SCOOP). SCOOP [17]
aims to explore the effectiveness of screening women aged 70–85
for the prevention of fractures using a risk-prediction algorithm.
The qualitative study took place in Norfolk, United Kingdom.
Ethics Statement
We secured approval from North West National Health Service
Research Ethics Committee (Ref: 07/H1010/70). Written in-
formed consent was obtained from participants. Two participants
with mild cognitive impairment were supported in the consenting
and interview process by their husbands.
The research comprised a longitudinal design with two in-depth
interviews conducted 18 months apart, the first at around 6
months post-randomisation. The sample was drawn from those
found to be at ‘higher than average’ risk of a subsequent fracture
and whose prescribing data showed they had started medications
for the prevention of osteoporosis. Participants were purposively
sampled from demographic and adherence data already collected
by the SCOOP trial (see Table 1). As the focus of our study was to
explore why older women were adherent, we constructed our
sample to include more women self-reporting they were adherent
when contacted by phone than reporting they were non-adherent
to their osteoporosis medication.
For the purpose of this study ‘adherent’ included both women
stating they were taking bisphosphonate medication as instructed,
and those stating they were intentionally or unintentionally
missing doses but no more than 1 in 5 (i.e. 80% adherence or
more). Non-adherent’ included all those who had discontinued
bisphosphonate medication, or were taking them ,80% of the
time, but who might still be taking prescribed supplements
(calcium and vitamin D).
The interviews
Interviews took place at participants’ homes and lasted an
average of 74 minutes. They were based on a topic guide
developed to explore women’s understanding of osteoporosis,
responses to screening results, current usage of preventive
medicine, motivators and detractors from taking medication and
follow up with healthcare professionals. Interview recordings were
transcribed verbatim and anonymised. Familiarisation, data
management, coding and categorisation were carried out by the
interdisciplinary research team including CS, LM and AH.
Iteration between both data sets and the research literature
helped inform the analysis at the explanatory level. The principles
of Framework Analysis [18] were used to order, chart and search
the data both manually and supported by relevant software
(NVivo 9 Software, MSWord and Framework). Illustrative
quotations are selected to elucidate the study findings. Extracts
are labelled using participant number, age at interview and
summary adherence status to both bisphosphonates and calcium
supplements.
Results
Ninety women in the ‘higher than average’ risk group recruited
to the Norwich arm of the SCOOP Trial indicated they would be
willing to take part in the qualitative sub-study. From these we
recruited a sample of 30 (33%) women, age range 73–85 years
(Table 1). Five participants were unable to participate in the
follow-up interview due to death or withdrawal from the study.
Understanding adherence and non-adherence
All 30 participants were prescribed bisphosphonates and all
except one commenced their first course. Of the 10 participants
shown in Table 2 who reported being non-adherent at Phase 1
Interviews, nine made this decision without discussion with their
Adherence to Osteoporosis Medicine
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general pracitioner. All bar one said they had done this within a
month of collecting their first prescription. The combination of
bisphosphonate and calcium: vitamin D supplements was reported
to be taken by 12 participants.
Of the 25 participants who took part in Phase 2 Interviews,
thirteen had remained adherent to bisphosphonate medication
and one previously non-adherent participant reported she had
started taking her medication as prescribed. Eleven were non-
adherent including three women that had given up their
bisphosphonate medicine between interviews. Thus, a significant
proportion of our sample were taking no medication for the
prevention of fracture and osteoporosis at 18 months (44%). Even
within the ‘adherent’ group, many women admitted deficits in
their adherence; sometimes this was deliberate, to avoid inconve-
nience, sometimes it was because they forgot one day, but took it
the next.
We found no obvious pattern or factors linking with adherence.
Responses to screening, acceptance of risk status, existing medical
history, previous experience of falls, fractures and family history
did not appear to predict womens’ adherence status.
Some participants complained about the complexity of the
regimen, many had experienced side effects, some said their
general practitioner had stopped the medication, and some had
misunderstood the reasons for taking them long-term. However,
many adherent women reported similar issues. Few cited
‘forgetting’ as a key cause of non-adherence. Almost all
respondents declared a willingness to ‘in principle’ do what their
general practitioner advised, but some non-adherent women cited
medical permission or support for their choice to stop:
He was quite happy, he said alright just stop. He said we’ve
had no broken bones in your family, he said you’ll probably
be quite alright. (Participant 12, age 84 – became Non-
Adherent to Bisphosphonates by Phase 2. Refused Calcium)
Personal scepticism about the value of the treatments did not
seem to link clearly with non-adherence. For example, the
following participant was adherent to her medications, but
demonstrated very little belief that she needed them at her age:
I thought well yes I am 80, so I probably have anyway
(thinning bones) and I also thought it is a bit late to start
treating me now I honestly did. That was my sort of attitude
but the letter said ‘go and see your doctor’, so I went and
saw my doctor and he gave me those. (Participant 24, age 80
Table 1. Sample characteristics using pre-collected trial data.
Sample Characteristic Category Number (%)
Self-reported adherence status given on phone at
recruitment
Adherent
Non-adherent
19 (63)
11 (37)
Age 70–74
75–79
80+
9 (30)
10 (33)
11 (37)
GP practice Urban
Rural
14 (47)
16 (53)
Social class I
II
IIIN
IIIM
IV
V
3 (10)
6 (20)
6 (20)
10 (33)
5 (17)
0
doi:10.1371/journal.pone.0083552.t001
Table 2. Summary of Patterns of Adherence.
Bisphosphonates Calcium Supplements
Bisphosphonates & Calcium
Supplements
N (%) N (%) N (%)
Phase 1
Adherent 20 (67) 15 (50) 12 (40)
Non-adherent 10 (33) 10 (33) 13 (43)
Not prescribed - 5 (17) 5 (17)
Total 30 (100) 30 (100) 30 (100)
Phase 2
Adherent 14 (56) 12 (48) 9 (36)
Non-adherent 11 (44) 9 (36) 12 (48)
Not prescribed - 4 (16) 4 (16)
Total 25 (100) 25 (100) 25 (100)
doi:10.1371/journal.pone.0083552.t002
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- Adherent to both Bisphosphonates & Calcium Phase 1,
subsequently withdrew)
By contrast Participant 22 was non-adherent. She felt anyone
could break a bone in the next 10 years and would have expected
to fracture by now if she was really at risk. She described how her
own mother had fallen and broken her hip yet appeared to remain
personally unconcerned:
When they said well look ‘a higher risk of breaking a bone
over the next 10 years’ and I thought well I’m over 80 so it’s not
surprising (laughs). (Participant 22, age 84 – Continually Non-
Adherent to both Bisphosphonates & Calcium)
Motivations, self-care and adherence
All the respondents regardless of adherence status seemed to
have accepted the need for better self-care and an altered lifestyle
in order to prevent fractures. Many believed they had been doing
this all their lives through a good diet, plenty of physical activity
and exercise:
Because I’ve always taken calcium you know. I’ve always
had a lot of cheese, a lot of yoghurt and I drink a certain
amount of milk I have calcium and I have a lot of vegetables.
(Participant 10, age 73 - Continually adherent bisphospho-
nates. Calcium not prescribed)
I take a cod liver oil pill every day, winter and summer. I’m
sure that’s a help. (Participant 09, age 85 - Continually non-
adherent bisphosphonates & calcium)
In addition, many participants had adjusted their daily routines
to enhance their capacity to take their regimens as prescribed.
Weekly doses were linked with memorable events, and chores such
as ironing utilised to fulfil the half hour required in remaining
upright:
So I try and get up early, take it with this load of water and
find something to do standing up, whether it’s ironing for an
hour which I did this week (laughs) or going round the
garden seeing what’s in flower. You have just got to find
something to do which takes your mind off it. (Participant
06, age 80 – Continually Adherent to Bisphosphonates.
Non-adherent to Calcium)
Market day is a Wednesday and I always used to go down to
buy plants every Wednesday. I always used to think I can’t
go down and get any plants, so I always remember
Wednesday. That was my day. (Participant 30, age 75 –
Continually Non-Adherent to Bisphosphonates. Took Cal-
cium supplements at Phase 2)
Carers played a role in aiding adherence for two participants
with cognitive impairments by bringing the medication to them
and altering the routine to ensure no food or cup of tea at the same
time:
He’d put it on his computer to remind me (and) he puts
them in front of me and lets me get on with it. (Participant
17, age 75 – Continually Adherent Bisphosphonates.
Calcium not prescribed).
Autonomy was also a powerful motivator, characterised by the
need to be independent and responsible in order to be able to care
for self and others:
Well it is just the independence. I don’t want to be a
nuisance to the family at all if I can help it, and if I haven’t
done something that might have helped I’d feel a bit guilty.
If you can do anything to prevent that happening it does
help a little bit. (Participant 03, age 83 – Continually
Adherent Bisphosphonates. Calcium not prescribed)
I like to protect myself as much as possible for my husband,
well for me (too) for me I mean obviously. (Participant 18,
age 80 – Non-Adherent Bisphosphonates by Phase 2. Non-
adherent to Calcium)
Appraising and prioritising risk
Phase 1 interviews specifically asked participants about their
reaction to their recent risk assessment. Risk perceptions at this
phase were mostly expressed in ‘sense making’ comments
regarding the context of ageing. There was added complexity
for participants who had been given a risk status of ‘higher than
average’ but had no visible signs or experience of symptoms:
Not in a million years. I thought oh they’ll come back and say
oh you’re fine. And they wrote back and said I wasn’t. Yes I
thought I couldn’t believe it because I’ve always had a
balanced diet. (Participant 29, age 75 – Continually
Adherent to both Bisphosphonates & Calcium)
Many of those who had initially questioned their risk status and
expressed negative reactions had adjusted to their status and cited
measures taken to be self-protective such as not climbing ladders
and prioritising a calcium rich diet:
Oh yeah it’s made me more careful since I had that density
scan and had the letter to say that um (pause) you know on
average, if I fell over I would more easily break a bone than
you know than normal. So that was a good thing because it
has made me more (careful) and as you notice, I’ve got no
rugs. (Participant 24, age 80 - Adherent to both Bisphos-
phonates & Calcium Phase 1, subsequently withdrew)
We explored the data for links between positive self-caring
attitudes (as exemplified by women in the first interviews giving
examples of longstanding commitment to weight bearing exercise
and good nutrition) and active embracing of pharmacological
options for preventing fractures. We also looked for an interre-
lationship between women’s ‘accepting’ versus ‘questioning’ of
their risk assessment and adherence to prescribed medication,
including their reported participation in the decision making
process and recourse to other support and information. Neither
state appeared to be linked with long-term adherence with equal
numbers of women remaining adherent to their medication who
were ‘questioning’ (n = 7) as ‘accepting’ (n = 7). Furthermore, there
was no link to adherence from either an initial strong emotive
reaction or passive acceptance. For example, the following initially
Adherence to Osteoporosis Medicine
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adherent participant had moved from a state of shock to positive
acceptance, and yet gave up on her medication within a year:
Well in a way when I got over the shock I thought well I
know something more about my body. (Participant 07, age
74 - Became Non- Adherent to Bisphosphonates by Phase 2.
Adherent to Calcium)
However, the long-term and hidden changes of bones which
‘thin’ or ‘crumble’ seemed a lower priority than other illnesses.
Participants’ recall of medication reviews mirrored this, with most
women reporting that their osteoporosis medications was rarely
reviewed or mentioned in consultations.
Anticipating and managing side effects
Eighteen women experienced side effects from mild to very
severe. These ranged from unsettled stomach problems to violent
nausea, vomiting bile, and burning:
They’re horrible they really were. Well I mean honestly I got
a really sore stomach and then on Monday my stomach was
really bad and honestly it just felt full of air and I’d touch it
and it was sore. (Participant 24, age 80 - Adherent to both
Bisphosphonates & Calcium Phase 1, subsequently with-
drew)
While severe side effects were linked to non-adherence, there
was no simple relationship between side effects and persisting with
medication, some trying up to 3 different medications. In fact, the
anticipation of side effects seemed to be enough to put off some
participants, with three in particular reporting that they were put
off by the possible side effects described in the medicines
information leaflet. Even the name ‘alendronic acid’ was cause
for concern for some:
Because it says acid (laughs). It isn’t a natural thing. I just
don’t like the idea of taking an acid and not lying down.
(Participant 13, age 75 – became adherent by Phase 2.
Adherent to Calcium)
The need for support concerning side effects was also
highlighted by a number of non-adherent women who anticipated
side effects that might aggravate existing problems:
To me it seemed more important that I, you know, (avoid)
this reflux than breaking my hip because I thought I can be
careful. (Participant 23, age 81 – tried one Bisphosphonate
tablet only. Non-starter Calcium)
The tablets that he gave me when I read the side effects it
was like a horror film really. And I thought well I’m better off
chancing, sort of breaking a bone, than all the horrible
things it said on there about (how) you could get these
stomach ulcers and all things like that. And I do suffer sort of
with heartburn and things like that. You have to sort of keep
upright for so long after taking the tablets. I thought well I’m
better off as I am than more things wrong really. (Participant
21, age 75 – non-starter Bisphosphonates and Calcium)
Problems of understanding
A number of problems of understanding were evident in the
interviews regarding osteoporosis risk, prevention and manage-
ment in older women. Although there was fear and concern about
developing osteoporosis, there was also a perception that falling
and fracturing were normal in old age. Others debated the
magnitude of risk, especially when compared to problems such as
diabetes and heart disease. Some women questioned why the Dual
energy X-ray Absorbtiometry screening had not been repeated to
monitor the effectiveness of the medication. Nine patients
adherent at Phase 1 mentioned this specifically, and 3 of these
had become non-adherent by Phase 2:
I really would like to have another scan to see how my body
is now, if it’s any worse or still the same or whatever. I’d like
to do that but apparently they don’t, they like to leave it a
certain amount of years don’t they? I’ve read that.
(Participant 24, age 80 - Adherent to both Bisphosphonates
& Calcium Phase 1, subsequently withdrew)
I mean if you’re going through all that performance, well it
was for me with the lack of being able to swallow, but if you
think you are doing that to no avail, you think well what’s
the point. (Participant 25, age 77 - became Non-adherent to
Bisphosphonates & Calcium Phase 2)
A number of women in both groups expressed significant
confusion about the nature and importance of the risk portrayed
by the positive screening result. There was also confusion between
falls and fractures, with some participants talking about their
fracture risk in terms of instability rather than fragility:
As I say, I would have thought somebody with osteoporosis
would have fallen over and broken their bones. (Participant
07, age 74 - Non adherent to Bisphosphonates by Phase 2.
Adherent to Calcium)
I was surprised because I felt that I’d not had a lot of falls or
tottery or anything. I thought people that were at higher risk
were inclined to fall. (Participant 01, age 75 - Continually
Adherent to Bisphosphonates. Took Calcium intermittently)
So I thought well that (bisphosphonate medication) will
prevent me falling cos the main reason was if my bones got
stronger I could do more in the garden and things like that
and get on the steps more often. I can’t anyway cos I get
dizzy (but) that was my thoughts. (Participant 30, age 75 -
Continually Non adherent to Bisphosphonates. Took
Calcium at Phase 2)
Confusion about the effectiveness of the medication was
common and participants frequently reflected on ‘not knowing’
if they were getting any benefit from taking the medication or not.
Participant 16 was fully adherent with no side effects, but felt it was
‘discouraging not knowing if it works’, as did others:
I suppose the fact of never having broken anything coupled
with the fact there’s no signal in your body is there? There’s
nothing that tells you that there is anything wrong, so you
Adherence to Osteoporosis Medicine
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don’t feel that there’s anything wrong. (Participant 08, age
75 – Continually Adherence Bisphosphonates and Calcium)
Decision making around medication
Overall we found clear if unpredictable narratives around
medication choice, with key factors being the initial result, side
effects and subsequent health service intervention of medication
prescription. Decisions were reviewed in a number of situations
and personal costs weighed up against perceived benefits of taking
the medication. Participant 09 described how she made the
decision in the light of her own understanding of her needs and the
relative benefit of taking the medication. She made her final
decision in consultation with her doctor:
There is no bone disease or any sign of it in our family but I
said I would take it and see what happened. It didn’t suit me
and I said I’m not taking them anymore and he (doctor)
agreed. He said ‘it’s no good taking them if they upset you
because your diabetes is more important’. (Participant 09,
age 85 – became non adherent by Phase 2 to Bisphospho-
nates and Calcium)
Many of those non-adherent to bisphosphonate medication at
Phase 2 had not asked for, or been offered, a change of medication
(n = 10). However, five women still adherent to their medications
and experiencing side effects had been back to their doctor at least
once for an alternative prescription by Phase 2 (Table 3).
Although most participants cited encouragement by doctors,
pharmacists, family, friends and the media, only three participants
specifically mentioned any sort of formal follow-up (one at a
diabetic review, one with a pharmacist and one with a nurse).
Many felt specific follow-up would have given them more
confidence:
I mean I’m all for taking it if I know what it’s doing and if it’s
doing you good, but there’s no follow up on these things. I
have to go and get my blood pressure taken every six
months. I feel like they know what’s going on cos they have
changed the different strengths at different times you know
depending on how my blood pressure is. But you don’t get
any follow up with this…. I think they need to have more
follow up on this. I’m taking it because it’s doing me what
it’s supposed to be doing, but it’s the not knowing and it’s
the not having the follow up to see whether you need to be
taking it or not. (Participant 11, age 77 – Continually
Adherent Bisphosphonates. Calcium not prescribed)
One participant explicitly changed her mind and became
adherent by Phase 2 having previously rejected the medication
because of her doctor’s insistence:
I didn’t used to take that but then once I had this
polymyalgia and I had to take the steroids. As I walked
out of the doctors’ room she said ‘now look you must take
that acid tablet because if not your bones will just crumble’.
So whether I like it or not I’m taking it. (Participant 13, age
75 – became adherent by Phase 2. Adherent to Calcium)
In summary, many participants saw the medication as an
adjunct to their own efforts to remain healthy and ward off the
impacts of ageing. Additional convenience of medication dosing, a
less off-putting name, and ways to reduce side effects would be
likely to positively influence people’s decisions to remain adherent
to these medications.
Discussion
The data overall show a group of resilient older women doing
their best to make sense of a particular set of health opportunities
in their lives, and keen to manage the impacts of ageing and
minimise increasing frailty and dependence. There was evidence
that those who had engaged with professionals to establish and
maintain regimens could tolerate and overcome barriers to
adherence which had defeated others. The variation of adherence
over time suggests that health professionals should not assume
adherence in any older women who has relevant medication on
their repeat medication list, and that the uncertainty of risk and
desire not to worry participants must not confuse messages that
these drugs can have a real positive health gain.
To our knowledge, no previous studies have undertaken
longitudinal in depth interviews to identify factors which influence
adherence to osteoporosis regimens in women who have been
identified at high risk of fracture. Thus, the strength of this study is
the repeat in depth interviews with older women that enabled
follow up and discussion of change overtime. The limitations
include potential sample bias: women who are keen to help
research are potentially more motivated to self-care and take an
active part in their own health.
However the context of this work is multifaceted and reflects the
issues that arise following screening in a cohort of women who
have not previously sought advice about their bone health.
Overtime many medications that are routinely prescribed become
objects embedded within everyday life and invested with particular
meanings, values and identities [19]. However, our findings
underline the fact that medications are complex social phenomena
that may take time to embed and become routinized and
acceptable to patients and healthcare professionals alike [20].
Medications, particularly medication prescribed prophylactically,
have many levels of meaning [21]. Bisphosphonate medication for
the prevention of osteoporosis and fracture is currently framed by
a more complex social context where understanding, choice, risk
and perceived need all interact to produce unpredictable patterns
of usage and acceptability [22].
This study did not record consultation data or the perspective of
general practitioners on their interactions around decision making
on bisphosphonates. In depth sociolinguistic research has high-
lighted that patients talk and deploy different discourses and
narratives depending on both the context and on the interactional
resources available to them [23], [24], [25], [26]. Although most
patients and their health care providers are likely to be keen to
ensure that they utilise the outputs of modern medical advances,
Table 3. Summary of Bisphosphonate medication changes
and adherence for participants that experienced side effects
at Phase 2 (n = 18).
Adherent Non-adherent
No change 2 (11) 10 (56)
Changed once 4 (22) 0
Changed twice 1 (6) 1 (6)
Total 7 (39) 11 (61)
doi:10.1371/journal.pone.0083552.t003
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this is in the context of the increasing biomedicalisation of life,
especially as people in developed countries are living longer [27].
Whether this is framed as a sophisticated commercial exploitation
of societal fears of frailty and death, or as an unpredicted
consequence of applying multiple disease related guidelines
without considering the overall impact, there are consequences
for individuals in making choices about their health-related
practices each day. For example, recent authors have pointed
out the likelihood of older people routinely being in receipt of
multiple medications, even if they have not yet developed any
specific disease [28], [29]. The cumulative costs of screenings,
follow-ups, treatments and personal sequelae in terms of time, side
effects, and perceived vulnerability or risk all need to be set against
the potential benefits. The impacts of knowing that they are
deemed to be at risk can move people from a narrative of their self
as a healthy empowered person to one who is frail and in need of
help, which can also have unexpected consequences [27].
Within this complex context, each patient and their doctor or
nurse has to make individual decisions as to whether a risk factor
should be prioritised or treated once detected. General practi-
tioners are probably the medical professionals who are most aware
of the extent to which the uptake of any new test or treatment is
dependent on the beliefs, understanding, needs and expectations of
the individual in front of them. It is a tenet of their discipline and
training that any new health issue needs to be debated in the
context of the person’s whole life context, while maximising health
gain and minimising adverse consequences of any intervention. It
is the skill of a general practitioner to enable patients to make
considered judgements in the face of these multiple choices.
However, both the literature and our interviews suggest that
preventive health measures often pose a challenge in time limited
appointments, which may have influenced the decision made in
some clinical encounters [30], [31], [32]. Furthermore, the fact
that this was a research study may also have influenced overall
uptake and follow-up in clinical practice. More research is needed
on the effectiveness and efficacy of secondary prevention and the
role of healthcare providers in this field.
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